It is in Geneva, the city of 44 Nobel Prizes, that Promindus, part of the Laprophan group, was awarded the Innovation Prize by the World Intellectual Property Organization (WIPO), presented during the 3rd Economic Symposium of the Swiss Moroccan Foundation for Sustainable Development on October 3, 2008, in the presence of high-ranking national and international bodies in the fields of economy and health - with the WHO and WIPO represented by their General Management.

According to the Director General of WIPO, “the awards given by WIPO are recognized internationally as among the most prestigious honors awarded to inventors and creators.”

This prestigious award is therefore a recognition of the innovative research of Laprophan Laboratories for developing the first anti-secretory medication in the class of PPIs (proton pump inhibitors) in effervescent form known by the brand name IXOR®.

IXOR® is a technological innovation as it is the first effervescent PPI based on omeprazole and a therapeutic innovation since the durable pharmacological activity of the PPI is associated with instant antacid action. This dual action, demonstrated by human pharmacological-clinical studies, significantly improves patient comfort throughout the treatment.

IXOR® has been the subject of an international invention patent, similar to other specialties of the Laprophan group, including Neofortan® and Di-Indo®. We would like to remind that this specialty was awarded the national prize by the R&D Morocco Association, which unanimously granted it the 1st prize for innovation.